Special Issue

Bone Marrow Transplantation

Submission Deadline: February 28, 2027 (Open) Submit Now

Guest Editor

Mohamed M. Khamis, MD, MS

Department of Medicine, Mercy Hospital St. Louis, St. Louis, MO, United States

Website1 | Website2 | E-Mail

Research Interests: Allogeneic and autologous hematopoietic stem cell transplantation (HSCT); BMT outcomes; Leukemia (AML, ALL, CML); Lymphoma and multiple myeloma; Myelodysplastic syndromes (MDS); Precision medicine and genomic profiling

About This Topic

Hematopoietic stem cell transplantation (HSCT) remains a cornerstone curative therapy for hematologic malignancies, bone marrow failure syndromes, and select inherited metabolic disorders. Over the past decade, the field has evolved substantially. Refined conditioning regimens, expanded donor platforms — including haploidentical and unrelated donors — and a deeper understanding of graft-versus-host disease (GvHD) biology have together broadened patient eligibility and improved survival.

The therapeutic landscape has also shifted with the rise of CAR-T cell therapies, off-the-shelf cellular products, and immune checkpoint modulation. These modalities now raise practical questions about how they sequence with, or in some cases replace, traditional transplantation. Meanwhile, advances in supportive care — particularly microbiome-directed interventions and infection prophylaxis — continue to reduce transplant-related morbidity and improve quality of life.

This Special Issue welcomes original research, reviews, and case reports addressing the full scope of BMT and HSCT. We invite contributions that bridge basic immunobiology, translational science, and clinical practice to move the field forward.

Keywords

Hematopoietic stem cell transplantation; bone marrow transplantation; graft-versus-host disease; allogeneic transplantation; autologous transplantation; CAR-T cell therapy; haploidentical transplantation; conditioning regimens; donor selection; gut microbiome; cellular therapy; immune reconstitution; precision medicine; checkpoint inhibition; post-transplant outcomes

Manuscript Submission Information

Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (transplantation@lidsen.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.

Welcome your submission!